Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ITWO vs INKT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ITWO Captures Overall Composite Edge (32.6 SELL vs 42.8 HOLD), While INKT Leads 3–0 on Growth & Valuation Pillars

ITWO Overall Winner 6-Pillar Tally: ITWO 0 – 3 INKT (3 Tie) Matrix Metrics: ITWO 2 – 6 INKT

As of Nov 20, 2026, ProShares Russell 2000 High Income ETF (ITWO) captures the overall head-to-head institutional edge over MiNK Therapeutics, Inc. (INKT) on higher Unified Composite conviction (32.6/100 SELL vs. 42.8/100 HOLD) after splitting the core matrix 2–6 (led by composite factor balance), while INKT wins 3–0 across the 6-pillar growth and valuation breakdown. ITWO trades at $39.26 (N/M Forward P/E, N/A operating margin) versus INKT at $8.02 (N/M Forward P/E, -5720.7% operating margin).

  • Composite vs. Pillar Nuance: While INKT currently prints a higher short-term Unified Composite Score (42.8/100 HOLD vs. ITWO 32.6/100 SELL), ITWO captures the overall institutional head-to-head verdict (2–6 matrix metrics and 0–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. -5720.7% operating margin) and revenue trajectory (N/A vs. +0.0% YoY).
  • Technical & Structure Timing Caution: ITWO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0); meanwhile INKT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ITWO vs INKT
ITWO Cboe BZX Head-to-Head Winner
ProShares Russell 2000 High Income ETF
Institutional Equity
$39.26
-2.89% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.02β · 26% Vol
Unified Composite Score
32.6 / 100 SELL
Tech 10.0 Fund 43.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.0%), weak momentum, RSI 29
RSI-14: 29.0 · SMA20: $42.50 · SMA50: $42.90
INKT NASDAQ
MiNK Therapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$8.02
-6.85% 1D
Market Cap $44.2M
TTM Revenue $200,000
Forward P/E N/M
Beta / 30D Vol 0.59β · 55% Vol
Unified Composite Score
42.8 / 100 HOLD
Tech 33.0 Fund 45.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.5%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $9.98 · SMA50: $10.80

6-Pillar Scorecard Institutional Category Breakdown (ITWO 0 – 3 INKT)

Columns: Metric · ITWO · INKT
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale INKT
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $200,000
Market Cap N/A $44.2M
3. Profitability & Quality INKT
Gross Margin N/A 100.0%
Operating Margin N/A -5720.7%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -1239.0%
4. Balance Sheet & Cash Flow INKT
Cash Generation (TTM) N/A -$6.3M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE -1239.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 27.5% (50th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ITWO (2) vs INKT (6)
Institutional Metric ITWO INKT Criterion Row Edge
Market Capitalization
Scale
N/A $44.2M Larger Scale INKT
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth INKT
Operating Margin (TTM)
Profitability
N/A -5720.7% Higher Margin INKT
Net Profit Margin
Profitability
N/A 0.0% Higher Margin INKT
Return on Equity (ROE)
Capital Efficiency
N/A -1239.0% Higher ROE INKT
52-Week Range Position
Momentum
22% ($37–$47) 3% ($8–$17) Stronger Trend ITWO
Beta / 30D Volatility
Risk Regime
1.02β · 26% Vol 0.59β · 55% Vol Lower Realized Risk ITWO
Unified Institutional Score
Composite Signal
32.6 / 100 (SELL) 42.8 / 100 (HOLD) Higher Composite INKT
Trailing 12M Revenue (USD)
Operating Scale
N/A $200,000 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$6.3M (-1239.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ITWO +12.23 pp
ITWO: -8.05% · INKT: -20.28%
3M Horizon ITWO +17.35 pp
ITWO: -14.8% · INKT: -32.15%
6M Horizon ITWO +14.58 pp
ITWO: -11.64% · INKT: -26.22%
1Y Horizon ITWO +31.36 pp
ITWO: +4.14% · INKT: -27.22%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ITWO vs INKT. Trailing 12-month operating profitability (ITWO N/A vs INKT -5720.7%) and valuation multiples (ITWO N/M vs INKT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ITWO ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
INKT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$200,000
Gross Margin100.0%
Op. Margin-5720.7%
ROE / Fwd P/E-1239.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ITWO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 27.5%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ITWO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INKT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact INKT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ITWO Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INKT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $44.2M market capitalization and -5720.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ITWO vs INKT Key Questions & Quantitative Answers

As of Nov 20, 2026, ProShares Russell 2000 High Income ETF (ITWO) captures the overall head-to-head institutional edge over MiNK Therapeutics, Inc. (INKT) on higher Unified Composite conviction (32.6/100 SELL vs. 42.8/100 HOLD) after splitting the core matrix 2–6 (led by composite factor balance), while INKT wins 3–0 across the 6-pillar growth and valuation breakdown. ITWO trades at $39.26 (N/M Forward P/E, N/A operating margin) versus INKT at $8.02 (N/M Forward P/E, -5720.7% operating margin). Composite vs. Pillar Nuance: While INKT currently prints a higher short-term Unified Composite Score (42.8/100 HOLD vs. ITWO 32.6/100 SELL), ITWO captures the overall institutional head-to-head verdict (2–6 matrix metrics and 0–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. -5720.7% operating margin) and revenue trajectory (N/A vs. +0.0% YoY). Technical & Structure Timing Caution: ITWO is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 29.0); meanwhile INKT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

INKT leads the Growth & Scale pillar: ITWO posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with INKT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $200,000 TTM revenue (100.0% gross margin, -5720.7% operating margin). On trailing 12-month operating scale, ITWO generates N/A in USD-normalized revenue versus $200,000 for INKT. In operating R&D and SG&A reinvestment, ITWO deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for INKT.

ITWO and INKT trade at balanced relative valuation multiples. ITWO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas INKT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ITWO (N/A ROE) versus INKT (-1239.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ITWO carries 27.5% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.02β · 26% Vol realized risk). By comparison, INKT carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 55% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.